Evaluating the Role of Methylated Circulating Tumor DNA in Combination With Pathological Prognostic Factors for Predicting Recurrence of Colorectal Cancer
CONCLUSIONS: Nodal invasion, metastatic disease, distal tumor site, low resection margins and perineural invasion were associated with disease recurrence. Pre-treatment methylated ctDNA measurement can improve the predictive value for recurrence in a subset of patients, particularly those with perineural involvement.REGISTRATION: Australian and New Zealand Clinical Trials Registry #12611000318987.PMID:38426070 | PMC:PMC10903227 | DOI:10.1177/11772719241232870 (Source: Biomarker Insights)
Source: Biomarker Insights - March 1, 2024 Category: General Medicine Authors: Hiba Al Naji Jean M Winter Susanne K Pedersen Amitesh Roy Susan E Byrne Graeme P Young Erin L Symonds Source Type: research

Evaluating the Role of Methylated Circulating Tumor DNA in Combination With Pathological Prognostic Factors for Predicting Recurrence of Colorectal Cancer
CONCLUSIONS: Nodal invasion, metastatic disease, distal tumor site, low resection margins and perineural invasion were associated with disease recurrence. Pre-treatment methylated ctDNA measurement can improve the predictive value for recurrence in a subset of patients, particularly those with perineural involvement.REGISTRATION: Australian and New Zealand Clinical Trials Registry #12611000318987.PMID:38426070 | PMC:PMC10903227 | DOI:10.1177/11772719241232870 (Source: Biomarker Insights)
Source: Biomarker Insights - March 1, 2024 Category: General Medicine Authors: Hiba Al Naji Jean M Winter Susanne K Pedersen Amitesh Roy Susan E Byrne Graeme P Young Erin L Symonds Source Type: research

Evaluating the Role of Methylated Circulating Tumor DNA in Combination With Pathological Prognostic Factors for Predicting Recurrence of Colorectal Cancer
CONCLUSIONS: Nodal invasion, metastatic disease, distal tumor site, low resection margins and perineural invasion were associated with disease recurrence. Pre-treatment methylated ctDNA measurement can improve the predictive value for recurrence in a subset of patients, particularly those with perineural involvement.REGISTRATION: Australian and New Zealand Clinical Trials Registry #12611000318987.PMID:38426070 | PMC:PMC10903227 | DOI:10.1177/11772719241232870 (Source: Biomarker Insights)
Source: Biomarker Insights - March 1, 2024 Category: General Medicine Authors: Hiba Al Naji Jean M Winter Susanne K Pedersen Amitesh Roy Susan E Byrne Graeme P Young Erin L Symonds Source Type: research

Evaluating the Role of Methylated Circulating Tumor DNA in Combination With Pathological Prognostic Factors for Predicting Recurrence of Colorectal Cancer
CONCLUSIONS: Nodal invasion, metastatic disease, distal tumor site, low resection margins and perineural invasion were associated with disease recurrence. Pre-treatment methylated ctDNA measurement can improve the predictive value for recurrence in a subset of patients, particularly those with perineural involvement.REGISTRATION: Australian and New Zealand Clinical Trials Registry #12611000318987.PMID:38426070 | PMC:PMC10903227 | DOI:10.1177/11772719241232870 (Source: Biomarker Insights)
Source: Biomarker Insights - March 1, 2024 Category: General Medicine Authors: Hiba Al Naji Jean M Winter Susanne K Pedersen Amitesh Roy Susan E Byrne Graeme P Young Erin L Symonds Source Type: research

Evaluating the Role of Methylated Circulating Tumor DNA in Combination With Pathological Prognostic Factors for Predicting Recurrence of Colorectal Cancer
CONCLUSIONS: Nodal invasion, metastatic disease, distal tumor site, low resection margins and perineural invasion were associated with disease recurrence. Pre-treatment methylated ctDNA measurement can improve the predictive value for recurrence in a subset of patients, particularly those with perineural involvement.REGISTRATION: Australian and New Zealand Clinical Trials Registry #12611000318987.PMID:38426070 | PMC:PMC10903227 | DOI:10.1177/11772719241232870 (Source: Biomarker Insights)
Source: Biomarker Insights - March 1, 2024 Category: General Medicine Authors: Hiba Al Naji Jean M Winter Susanne K Pedersen Amitesh Roy Susan E Byrne Graeme P Young Erin L Symonds Source Type: research

Evaluating the Role of Methylated Circulating Tumor DNA in Combination With Pathological Prognostic Factors for Predicting Recurrence of Colorectal Cancer
CONCLUSIONS: Nodal invasion, metastatic disease, distal tumor site, low resection margins and perineural invasion were associated with disease recurrence. Pre-treatment methylated ctDNA measurement can improve the predictive value for recurrence in a subset of patients, particularly those with perineural involvement.REGISTRATION: Australian and New Zealand Clinical Trials Registry #12611000318987.PMID:38426070 | PMC:PMC10903227 | DOI:10.1177/11772719241232870 (Source: Biomarker Insights)
Source: Biomarker Insights - March 1, 2024 Category: General Medicine Authors: Hiba Al Naji Jean M Winter Susanne K Pedersen Amitesh Roy Susan E Byrne Graeme P Young Erin L Symonds Source Type: research

Evaluating the Role of Methylated Circulating Tumor DNA in Combination With Pathological Prognostic Factors for Predicting Recurrence of Colorectal Cancer
CONCLUSIONS: Nodal invasion, metastatic disease, distal tumor site, low resection margins and perineural invasion were associated with disease recurrence. Pre-treatment methylated ctDNA measurement can improve the predictive value for recurrence in a subset of patients, particularly those with perineural involvement.REGISTRATION: Australian and New Zealand Clinical Trials Registry #12611000318987.PMID:38426070 | PMC:PMC10903227 | DOI:10.1177/11772719241232870 (Source: Biomarker Insights)
Source: Biomarker Insights - March 1, 2024 Category: General Medicine Authors: Hiba Al Naji Jean M Winter Susanne K Pedersen Amitesh Roy Susan E Byrne Graeme P Young Erin L Symonds Source Type: research

Evaluating the Role of Methylated Circulating Tumor DNA in Combination With Pathological Prognostic Factors for Predicting Recurrence of Colorectal Cancer
CONCLUSIONS: Nodal invasion, metastatic disease, distal tumor site, low resection margins and perineural invasion were associated with disease recurrence. Pre-treatment methylated ctDNA measurement can improve the predictive value for recurrence in a subset of patients, particularly those with perineural involvement.REGISTRATION: Australian and New Zealand Clinical Trials Registry #12611000318987.PMID:38426070 | PMC:PMC10903227 | DOI:10.1177/11772719241232870 (Source: Biomarker Insights)
Source: Biomarker Insights - March 1, 2024 Category: General Medicine Authors: Hiba Al Naji Jean M Winter Susanne K Pedersen Amitesh Roy Susan E Byrne Graeme P Young Erin L Symonds Source Type: research

Evaluating the Role of Methylated Circulating Tumor DNA in Combination With Pathological Prognostic Factors for Predicting Recurrence of Colorectal Cancer
CONCLUSIONS: Nodal invasion, metastatic disease, distal tumor site, low resection margins and perineural invasion were associated with disease recurrence. Pre-treatment methylated ctDNA measurement can improve the predictive value for recurrence in a subset of patients, particularly those with perineural involvement.REGISTRATION: Australian and New Zealand Clinical Trials Registry #12611000318987.PMID:38426070 | PMC:PMC10903227 | DOI:10.1177/11772719241232870 (Source: Biomarker Insights)
Source: Biomarker Insights - March 1, 2024 Category: General Medicine Authors: Hiba Al Naji Jean M Winter Susanne K Pedersen Amitesh Roy Susan E Byrne Graeme P Young Erin L Symonds Source Type: research

Evaluating the Role of Methylated Circulating Tumor DNA in Combination With Pathological Prognostic Factors for Predicting Recurrence of Colorectal Cancer
CONCLUSIONS: Nodal invasion, metastatic disease, distal tumor site, low resection margins and perineural invasion were associated with disease recurrence. Pre-treatment methylated ctDNA measurement can improve the predictive value for recurrence in a subset of patients, particularly those with perineural involvement.REGISTRATION: Australian and New Zealand Clinical Trials Registry #12611000318987.PMID:38426070 | PMC:PMC10903227 | DOI:10.1177/11772719241232870 (Source: Biomarker Insights)
Source: Biomarker Insights - March 1, 2024 Category: General Medicine Authors: Hiba Al Naji Jean M Winter Susanne K Pedersen Amitesh Roy Susan E Byrne Graeme P Young Erin L Symonds Source Type: research

Evaluating the Role of Methylated Circulating Tumor DNA in Combination With Pathological Prognostic Factors for Predicting Recurrence of Colorectal Cancer
CONCLUSIONS: Nodal invasion, metastatic disease, distal tumor site, low resection margins and perineural invasion were associated with disease recurrence. Pre-treatment methylated ctDNA measurement can improve the predictive value for recurrence in a subset of patients, particularly those with perineural involvement.REGISTRATION: Australian and New Zealand Clinical Trials Registry #12611000318987.PMID:38426070 | PMC:PMC10903227 | DOI:10.1177/11772719241232870 (Source: Biomarker Insights)
Source: Biomarker Insights - March 1, 2024 Category: General Medicine Authors: Hiba Al Naji Jean M Winter Susanne K Pedersen Amitesh Roy Susan E Byrne Graeme P Young Erin L Symonds Source Type: research

Evaluating the Role of Methylated Circulating Tumor DNA in Combination With Pathological Prognostic Factors for Predicting Recurrence of Colorectal Cancer
CONCLUSIONS: Nodal invasion, metastatic disease, distal tumor site, low resection margins and perineural invasion were associated with disease recurrence. Pre-treatment methylated ctDNA measurement can improve the predictive value for recurrence in a subset of patients, particularly those with perineural involvement.REGISTRATION: Australian and New Zealand Clinical Trials Registry #12611000318987.PMID:38426070 | PMC:PMC10903227 | DOI:10.1177/11772719241232870 (Source: Biomarker Insights)
Source: Biomarker Insights - March 1, 2024 Category: General Medicine Authors: Hiba Al Naji Jean M Winter Susanne K Pedersen Amitesh Roy Susan E Byrne Graeme P Young Erin L Symonds Source Type: research

Evaluating the Role of Methylated Circulating Tumor DNA in Combination With Pathological Prognostic Factors for Predicting Recurrence of Colorectal Cancer
CONCLUSIONS: Nodal invasion, metastatic disease, distal tumor site, low resection margins and perineural invasion were associated with disease recurrence. Pre-treatment methylated ctDNA measurement can improve the predictive value for recurrence in a subset of patients, particularly those with perineural involvement.REGISTRATION: Australian and New Zealand Clinical Trials Registry #12611000318987.PMID:38426070 | PMC:PMC10903227 | DOI:10.1177/11772719241232870 (Source: Biomarker Insights)
Source: Biomarker Insights - March 1, 2024 Category: General Medicine Authors: Hiba Al Naji Jean M Winter Susanne K Pedersen Amitesh Roy Susan E Byrne Graeme P Young Erin L Symonds Source Type: research

Evaluating the Role of Methylated Circulating Tumor DNA in Combination With Pathological Prognostic Factors for Predicting Recurrence of Colorectal Cancer
CONCLUSIONS: Nodal invasion, metastatic disease, distal tumor site, low resection margins and perineural invasion were associated with disease recurrence. Pre-treatment methylated ctDNA measurement can improve the predictive value for recurrence in a subset of patients, particularly those with perineural involvement.REGISTRATION: Australian and New Zealand Clinical Trials Registry #12611000318987.PMID:38426070 | PMC:PMC10903227 | DOI:10.1177/11772719241232870 (Source: Biomarker Insights)
Source: Biomarker Insights - March 1, 2024 Category: General Medicine Authors: Hiba Al Naji Jean M Winter Susanne K Pedersen Amitesh Roy Susan E Byrne Graeme P Young Erin L Symonds Source Type: research

Evaluating the Role of Methylated Circulating Tumor DNA in Combination With Pathological Prognostic Factors for Predicting Recurrence of Colorectal Cancer
CONCLUSIONS: Nodal invasion, metastatic disease, distal tumor site, low resection margins and perineural invasion were associated with disease recurrence. Pre-treatment methylated ctDNA measurement can improve the predictive value for recurrence in a subset of patients, particularly those with perineural involvement.REGISTRATION: Australian and New Zealand Clinical Trials Registry #12611000318987.PMID:38426070 | PMC:PMC10903227 | DOI:10.1177/11772719241232870 (Source: Biomarker Insights)
Source: Biomarker Insights - March 1, 2024 Category: General Medicine Authors: Hiba Al Naji Jean M Winter Susanne K Pedersen Amitesh Roy Susan E Byrne Graeme P Young Erin L Symonds Source Type: research